4MNA Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Minerva Neurosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.97 |
| 52 Week High | US$11.49 |
| 52 Week Low | US$1.89 |
| Beta | 0.17 |
| 11 Month Change | -10.45% |
| 3 Month Change | -17.92% |
| 1 Year Change | -60.60% |
| 33 Year Change | -69.49% |
| 5 Year Change | -95.60% |
| Change since IPO | -97.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4MNA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.2% | -1.1% | 1.1% |
| 1Y | -60.6% | -18.8% | 7.2% |
Return vs Industry: 4MNA underperformed the German Biotechs industry which returned -18.3% over the past year.
Return vs Market: 4MNA underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| 4MNA volatility | |
|---|---|
| 4MNA Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4MNA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4MNA's weekly volatility has decreased from 14% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 9 | Remy Luthringer | www.minervaneurosciences.com |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia.
Minerva Neurosciences, Inc. Fundamentals Summary
| 4MNA fundamental statistics | |
|---|---|
| Market cap | €14.36m |
| Earnings (TTM) | -€3.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.5x
P/E RatioIs 4MNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4MNA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$12.40m |
| Gross Profit | -US$12.40m |
| Other Expenses | -US$9.09m |
| Earnings | -US$3.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -276.9% |
How did 4MNA perform over the long term?
See historical performance and comparison